HC Wainwright Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $55.00

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price decreased by HC Wainwright from $60.00 to $55.00 in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on the stock. Truist Financial lifted their target price on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Canaccord Genuity Group raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and lifted their price objective for the company from $84.00 to $98.00 in a research note on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d)” rating on shares of BioMarin Pharmaceutical in a report on Monday, December 29th. Royal Bank Of Canada restated a “sector perform” rating and set a $66.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Finally, Sanford C. Bernstein cut their price target on shares of BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating on the stock in a research note on Monday, November 3rd. Fifteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $87.71.

BioMarin Pharmaceutical Trading Up 1.0%

Shares of BMRN stock opened at $61.73 on Wednesday. BioMarin Pharmaceutical has a 1-year low of $50.76 and a 1-year high of $73.51. The firm has a market cap of $11.86 billion, a PE ratio of 34.68, a price-to-earnings-growth ratio of 0.53 and a beta of 0.26. The company has a 50-day moving average of $58.91 and a two-hundred day moving average of $56.19. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.10.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the sale, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. This trade represents a 14.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by company insiders.

Institutional Trading of BioMarin Pharmaceutical

A number of large investors have recently made changes to their positions in the company. NewEdge Advisors LLC raised its holdings in BioMarin Pharmaceutical by 11.5% in the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock valued at $266,000 after acquiring an additional 388 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of BioMarin Pharmaceutical by 207.4% in the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock valued at $850,000 after purchasing an additional 8,112 shares in the last quarter. Focus Partners Wealth lifted its position in shares of BioMarin Pharmaceutical by 70.2% during the 1st quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock worth $835,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of BioMarin Pharmaceutical by 33.0% during the second quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 1,102 shares in the last quarter. Finally, D.A. Davidson & CO. grew its stake in shares of BioMarin Pharmaceutical by 4.9% during the second quarter. D.A. Davidson & CO. now owns 7,119 shares of the biotechnology company’s stock worth $391,000 after purchasing an additional 331 shares in the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Sanford C. Bernstein published a bullish forecast calling for strong price appreciation for BMRN, which can lift investor expectations ahead of upcoming catalysts. Sanford C. Bernstein Forecast
• Positive Sentiment: Wells Fargo flagged BMRN as an attractive buy ahead of the Transcon‑CNP PDUFA decision, highlighting regulatory upside as a near‑term positive catalyst. Wells Fargo note
• Neutral Sentiment: Coverage pieces analyzing recent share rebound and DCF upside present valuation arguments but offer no clear catalyst; useful for investors modeling scenarios but not an immediate price driver. Valuation/DCF analysis
• Neutral Sentiment: Reported short‑interest data is effectively zero and contains apparent data errors (showing increases of “NaN”); this appears to be a reporting glitch and does not signal a meaningful short squeeze or surge in bearish positioning. (data entries dated Feb 26–27)
• Negative Sentiment: EVP Gregory Friberg sold 6,326 shares for roughly $382k at an average $60.38 on Feb. 26 — an insider sale that can weigh on sentiment, especially given the size relative to his remaining stake. Insider sale filing
• Negative Sentiment: HC Wainwright published a pessimistic forecast for BMRN, which could pressure sentiment among more risk‑sensitive investors. HC Wainwright note
• Negative Sentiment: Oppenheimer lowered its price target to $95, a cut that may temper upside expectations despite other bullish targets — contributes to mixed analyst messaging. Oppenheimer target cut

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.